Salarius Pharmaceuticals, Inc. (SLRX) analyst actions
Rating and price-target actions on SLRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SLRX overview →
2 measured SLRX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers | Press release | +2.59% | +2.83% | |
| Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment | Press release | +4.33% | -4.66% |
Keep exploring
More SLRX: earnings → · SEC filings → · SLRX overview →